This trial studies a new treatment (ASP1002) for people with certain solid tumors. It aims to learn if it has any medical problems or side effects and to find a suitable dose to use in future studies. People will receive infusions & checks during visits over 2 years.
- Advanced Solid Tumors
8 Primary · 12 Secondary · Reporting Duration: Up to 28 months
4 Treatment Groups
Experimental: AS1002 Dose Expansion (Part 2) urothelial carcinoma (UC)
1 of 4
Experimental: ASP1002 Dose Expansion (Part 2) colorectal cancer (CRC)
1 of 4
ASP1002 Dose Escalation (Part 1)
1 of 4
ASP1002 Dose Expansion (Part 2) non-small cell lung cancer (NSCLC)
1 of 4
210 Total Participants · 4 Treatment Groups
Primary Treatment: Experimental: AS1002 Dose Expansion (Part 2) urothelial carcinoma (UC) · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
What possible harmful effects could result from administering ASP1002 Dose Escalation (Part 1) to patients?
"Due to the preliminary state of clinical research, our team at Power assigned ASP1002 Dose Escalation (Part 1) a score of one in terms of safety. This is because Phase 1 trials provide limited evidence regarding both efficacy and risk profiles." - Anonymous Online Contributor
How many individuals have elected to participate in this trial?
"Affirmative. According to information available on clinicaltrials.gov, this trial is actively recruiting patients since its posting date of February 21st 2023 and was last updated on March 7th 2023. 210 individuals need to be enrolled across two medical locations." - Anonymous Online Contributor
Is it still possible for individuals to join this clinical experiment?
"Per the clinicaltrials.gov website, this experiment is currently recruiting volunteers and has been receiving updates since its initiation on February 21st 2023. The most recent edit was made on March 7th of the same year." - Anonymous Online Contributor
What are the desired outcomes for this medical experiment?
"The sponsor of this medical trial, Astellas Pharma Global Development Inc., has outlined the primary outcome as Adverse Events (AEs) and physical exam abnormalities over a 24 month period. Secondary outcomes span from Maximum concentration (Cmax), Duration of Response (DOR), to Disease Control Rate (DCR)." - Anonymous Online Contributor